Litcius/Paper detail

Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19

Jonathan M. Samet

2020Nicotine & Tobacco Research22 citationsDOIOpen Access PDF

Abstract

IMPLICATIONS: This commentary addresses the state of the evidence on tobacco products, nicotine, and COVID-19. The evidence of the effects of smoking on respiratory infections and the immune system in general are examined and the current understanding of tobacco products and risk for SARS-CoV-2 infection and the course of COVID-19 is addressed.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBetacoronavirusSars virusVirologyMedicineEnvironmental healthCoronavirus InfectionsOutbreakInfectious disease (medical specialty)Internal medicineDiseaseCOVID-19 Clinical Research StudiesCancer, Stress, Anesthesia, and Immune ResponseNutritional Studies and Diet
Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19 | Litcius